MarketCap
Pacific Biosciences of California PACB
$ 2.22
-6.33%
Facebook
X
Telegram
Pacific Biosciences of California ROCE Ratio | PACB
Annual ROCE Ratio Pacific Biosciences of California
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -77.87 | -39.72 | -20.26 | -20.43 | -10.87 | -27.8 | -101.73 | -70.43 | -77.77 | -68.43 | -56.15 | -67.56 | -68.24 | -82.08 | -55.17 | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -10.87 | -101.73 | -56.3 |
Quarterly ROCE Ratio Pacific Biosciences of California
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -19.14 | -18.74 | -18.07 | -70.91 | -77.94 | -77.29 | -83.72 | -34.81 | -27.29 | -27.5 | -19.85 | -20.35 | -20.84 | -20.32 | -19.48 | -18.01 | -15.56 | -15.03 | -14.37 | -13.0 | -16.87 | -20.11 | -26.73 | -23.97 | -42.1 | -64.35 | -77.47 | -89.17 | -92.4 | -78.23 | -77.05 | -73.74 | -70.17 | -71.77 | -69.98 | -75.12 | -74.5 | -71.72 | -68.74 | -62.62 | -46.59 | -28.19 | -33.69 | -44.95 | -63.06 | -76.44 | -75.03 | -62.0 | -57.7 | -63.91 | -62.43 | -63.37 | -67.28 | -68.76 | -66.53 | -65.93 | -65.32 | -14.55 | -15.73 | - | - | - | -18.26 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -13.0 | -92.4 | -48.98 |
ROCE Ratio of other stocks in the Diagnostics research industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aspira Women's Health
AWH
|
114.15 | - | -6.19 % | $ 10.5 M |  USA |
 |
Check-Cap Ltd.
CHEK
|
-69.04 | - | - | $ 9.42 M |  Israel |
 |
Exact Sciences Corporation
EXAS
|
-8.59 | - | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
22.99 | $ 26.91 | 0.9 % | $ 602 M | USA |
 |
Twist Bioscience Corporation
TWST
|
-28.81 | $ 132.17 | -2.35 % | $ 7.9 B | USA |
 |
Organovo Holdings
ONVO
|
1045.22 | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
75.43 | - | -16.95 % | $ 1.54 M | USA |
 |
PerkinElmer
PKI
|
3.29 | - | -0.91 % | $ 14.7 B | USA |
 |
Soleno Therapeutics
SLNO
|
1.87 | - | - | $ 2.69 B | USA |
 |
Enzo Biochem
ENZ
|
-22.04 | - | -8.98 % | $ 14.8 K | USA |
 |
Waters Corporation
WAT
|
7.05 | $ 476.29 | -0.09 % | $ 28.4 B | USA |
 |
Exagen
XGN
|
-32.08 | $ 5.26 | -25.92 % | $ 113 M | USA |
 |
Celcuity
CELC
|
-40.76 | $ 67.13 | -4.11 % | $ 3.14 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.9 | $ 370.89 | -0.25 % | $ 30.9 B | USA |
 |
Lantheus Holdings
LNTH
|
16.41 | $ 101.65 | 0.63 % | $ 6.86 B | USA |
 |
Accelerate Diagnostics
AXDX
|
63.01 | - | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
116.53 | $ 664.97 | -1.18 % | $ 19.2 B | USA |
 |
Charles River Laboratories International
CRL
|
0.42 | $ 346.21 | -2.02 % | $ 17.2 B | USA |
 |
Mettler-Toledo International
MTD
|
35.8 | $ 1 750.2 | -0.69 % | $ 36.1 B |  Schweiz |
 |
Danaher Corporation
DHR
|
8.93 | $ 236.19 | 0.46 % | $ 168 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
7.33 | $ 30.39 | -1.32 % | $ 28.8 B |  Niderland |
 |
RadNet
RDNT
|
2.13 | $ 77.91 | -0.6 % | $ 5.86 B | USA |
 |
Senseonics Holdings
SENS
|
-67.05 | $ 10.05 | 2.55 % | $ 419 M | USA |
 |
Neuronetics
STIM
|
-29.33 | $ 2.01 | -7.8 % | $ 133 M | USA |
 |
T2 Biosystems
TTOO
|
177.14 | - | -39.35 % | $ 313 K | USA |
 |
Thermo Fisher Scientific
TMO
|
14.5 | $ 719.09 | -0.35 % | $ 271 B | USA |
 |
Biocept
BIOC
|
-360.98 | - | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
-25.56 | $ 155.43 | -2.12 % | $ 19.5 B | USA |
 |
Akumin
AKU
|
58.25 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
1.76 | $ 10.63 | -8.68 % | $ 361 M | Israel |
 |
VolitionRx Limited
VNRX
|
63.48 | $ 0.19 | -6.2 % | $ 23.9 M |  Singapore |
 |
Natera
NTRA
|
-15.84 | $ 311.81 | -1.92 % | $ 42.6 B | USA |
 |
IQVIA Holdings
IQV
|
10.16 | $ 275.46 | -1.21 % | $ 47.4 B | USA |
 |
Agilent Technologies
A
|
21.94 | $ 178.84 | -0.74 % | $ 50.8 B | USA |
 |
Quotient Limited
QTNT
|
72.05 | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Chembio Diagnostics
CEMI
|
-132.81 | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
-181.44 | - | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
-4.75 | - | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
-93.18 | - | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
11.54 | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
-443.13 | - | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
-4.81 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-219.45 | - | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
376.98 | - | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
-36.9 | - | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
13.43 | - | - | $ 1.49 B | USA |
 |
DexCom
DXCM
|
21.72 | $ 79.92 | -1.42 % | $ 31.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
21.7 | $ 258.38 | -0.5 % | $ 28.7 B | USA |
 |
Castle Biosciences
CSTL
|
-8.4 | $ 34.41 | 0.07 % | $ 997 M | USA |
 |
IDEXX Laboratories
IDXX
|
61.76 | $ 696.77 | -1.4 % | $ 56 B | USA |